What is the target price for Regeneron Pharmaceuticals (regn) stock?
18 brokers have issued 1 year target prices for Regeneron Pharmaceuticals' shares. Their predictions range from $320.00 to $480.00. On average, they expect Regeneron Pharmaceuticals' stock price to reach $385.38 in the next year.
What does regn stand for?
REGN: Regeneron Pharmaceuticals, Inc. 2021-08-24 07:00:00 Regeneron Announces Encouraging Topline Phase 2 Data of High-dose aflibercept in Wet Age-related Macular Degeneration Kemanakah hala tuju REGN selepas memecahkan Akk time high ? Adakah ombak 1 sudah berakhir?
Is there a free training available for reading Candlestick charts?
Click here for our free training. Want to learn more about how to read candlestick charts and candlestick patterns? Get started with our free training HERE Learn more about how to use this chart and all its features by watching this video: If playback doesn't begin shortly, try restarting your device.
See more
When will Regeneron report results?
Is Regeneron working with Decibel?
(NASDAQ: REGN) today announced that it will report its second quarter 2021 financial and operating results on Thursday, August 5, 2021, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
What does the green T on the stock chart mean?
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has extended the research term of its collaboration with Decibel Therapeutics Inc (NASDAQ: DBTX) to discover and develop gene therapies for hearing loss. The research term is extended to November 15, 2023, and Regeneron will pay Decibel an extension fee of $10 million in Q4 of 2022. Under the collaboration launched in 2017, Decibel is developing three gene therapy programs targeting congenital, monogenic hearing loss with Regeneron. Decibel plans to i
How much debt does Regeneron Pharmaceuticals have?
Bullish trend line bounce. The green "T" on the chart indicates a tweezer pattern which sometimes is a reversal. Appears to be finding some support, this stock is overall bullish. Thanks for viewing!
Can Regeneron break out of a triangle?
The company currently has 20 compounds under various stages of clinical development. It had debt of US$1.98b, up from none in one year. However, it does have US$3.59b in cash offsetting this, leading to net cash of US$1.61b.
What is the NASDAQ symbol for Regeneron?
Regeneron could break out of a triangle and at the same time break the downtrend. It already crossed 50 and 100 moving averages. feedback would be nice :)
When is Regeneron earnings call?
Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."
How much does Regeneron make?
Regeneron Pharmaceuticals will be holding an earnings conference call on Thursday, August 5th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.
What is Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals has a market capitalization of $62.47 billion and generates $8.50 billion in revenue each year. The biopharmaceutical company earns $3.51 billion in net income (profit) each year or $28.66 on an earnings per share basis.
When will Regeneron release its earnings?
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.
Does Regeneron pay dividends?
Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021. View our earnings forecast for Regeneron Pharmaceuticals.
What is Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals does not currently pay a dividend.
Does Regeneron have a gene for obesity?
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer, and bispecific antibodies and antibody cocktails with other collaborators and independently.
